Kidney Cancer Clinical Trials

Showing 1-14 of 14 items
1.
2.
3.
4.
  • Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
  • The purpose of this research study is to determine if the combination of sunitinib and gemcitabine is effective in treating patients with metastatic renal cell carcinoma. The safety of this combination will also be studied. Sunitinib is approved by the FDA for the treatment of renal cell carcinoma. However, some patients' cancers do not respond to treatment or stops responding after initially responding. Gemcitabine is a chemotherapy drug that is approved by the FDA for the treatment of pancreatic cancer and several other cancers. It is not approved for the treatment of renal cell carcinoma. Previous research has suggested that combining gemcitabine with sunitinib may have some effectiveness in treating metastatic renal cell carcinoma.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
5.
  • PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
  • CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug that are known to target specific cells (in this case, cells in the immune system) The DC RCC Vaccine is agent that tries to help the immune system to recognize and fight against cancer cells. The purpose of this research study is to determine the safety of CT-011 alone, and in combination with the Dendritic Cell Renal Cell Carcinoma (DC RCC) vaccine. The investigators are also trying to find out what effect the combination has on the disease, and on your immune system.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
6.
  • Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
  • BKM-120 is a drug that may slow the growth of cancer cells. This drug has been used in laboratory experiments and information from those research studies suggests that this drug may help to slow the growth of renal cancer cells. In this research study, the investigators are testing the safety to BKM-120 at different dose levels. The investigators will also be studying how well tolerated BKM-120 is, and how effective BKM-120 can be in the treatment of kidney cancer.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
7.
  • Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit
  • The purpose of this study is to see if the Neo-Urinary Conduit(NUC), which is made in the laboratory from a combination of a patient's own cells and other materials can be used to form a conduit to safety allow urine flow from the kidneys to outside the body after radical cystectomy in patients with bladder cancer.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
8.
9.
10.
11.
12.
13.
14.
Showing 1-14 of 14 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms